What is chimeric antigen receptor (CAR) T-cell therapy?

Updated: May 04, 2018
  • Author: Sameh Gaballa, MD, MS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Chimeric antigen receptor (CAR) T-cell therapy is an emerging cancer treatment modality in which the patients’ own immune cells are collected, genetically engineered to recognize a tumor-related target, expanded in vitro, and then reinfused to produce responses and prevent progression in a variety of malignancies (ie, adoptive cell transfer). [1] Several types of adoptive cell transfer are under investigation, but CAR T-cell therapy is the first to enter clinical practice.

Currently available techniques for producing CAR-T cells include retroviral vectors, plasmids, and gene editing with the evolving CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats–CRISPR-associated protein-9 nuclease) technology. In addition, considerable research continues to enhance current efforts as well as extend this approach to many tumor types.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!